These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36961579)

  • 1. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
    Santi Laurini G; Montanaro N; Motola D
    Eur J Clin Pharmacol; 2023 May; 79(5):657-661. PubMed ID: 36961579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
    Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
    Moro PL; Olson CK; Zhang B; Marquez P; Strid P
    Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 - October 2021.
    Moro PL; Olson CK; Clark E; Marquez P; Strid P; Ellington S; Zhang B; Mba-Jonas A; Alimchandani M; Cragan J; Moore C
    Vaccine; 2022 May; 40(24):3389-3394. PubMed ID: 35489985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
    Li Y; Li J; Dang Y; Chen Y; Tao C
    JMIR Public Health Surveill; 2024 Jul; 10():e51007. PubMed ID: 39008362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Santi Laurini G; Montanaro N; Broccoli M; Bonaldo G; Motola D
    Vaccine; 2023 May; 41(18):2879-2886. PubMed ID: 37024412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS).
    Shin J; Shim SR; Lee J; Ryu HS; Kim JY
    Front Public Health; 2023; 11():1338862. PubMed ID: 38269374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of COVID-19 vaccinations in the United States.
    Singh A; Khillan R; Mishra Y; Khurana S
    Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
    Rosenblum HG; Gee J; Liu R; Marquez PL; Zhang B; Strid P; Abara WE; McNeil MM; Myers TR; Hause AM; Su JR; Markowitz LE; Shimabukuro TT; Shay DK
    Lancet Infect Dis; 2022 Jun; 22(6):802-812. PubMed ID: 35271805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
    Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
    Front Immunol; 2022; 13():965171. PubMed ID: 36263025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting rates for VAERS death reports following COVID-19 vaccination, December 14, 2020-November 17, 2021.
    Day B; Menschik D; Thompson D; Jankosky C; Su J; Moro P; Zinderman C; Welsh K; Dimova RB; Nair N
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):763-772. PubMed ID: 36813704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS).
    Zhang B; Yu X; Liu J; Liu J; Liu P
    BMC Womens Health; 2022 Oct; 22(1):403. PubMed ID: 36195902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.